Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Ratings Summary on Apr 16, 2018

April 16, 2018 - By Ira Colvard

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Corporate Logo
Big Money Sentiment increased to 2.75 in 2017 Q4. It has change of 0.75, from 2017Q3’s 2. The ratio improved due to Oramed Pharmaceuticals Inc. positioning: 1 sold and 3 reduced. 4 funds acquired stakes and 7 increased stakes. Investors holded 255,973 in 2017Q3 but now own 329,110 shares or 28.57% more.
Susquehanna Grp Limited Liability Partnership holds 0% or 18,474 shs in its capital. Renaissance Technology Limited Liability Company holds 0% or 93,500 shs. Tower Rech Ltd Company (Trc) has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Group One Trading L P reported 11,477 shs or 0% of all its holdings. Jfs Wealth Advsr Lc has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 500 shs. Fin Architects reported 2,750 shs or 0% of all its holdings. Millennium Mgmt Ltd Liability Corp holds 15,849 shs. Morgan Stanley holds 0% or 35,994 shs. Savings Bank Of Montreal Can invested in 2,600 shs or 0% of the stock. Macquarie Gp Ltd stated it has 3,499 shs. Fincl Bank Of America De owns 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 1,117 shs. Glenmede Commerce Na accumulated 0% or 20,000 shs. 1,700 were accumulated by Jpmorgan Chase Company. Pnc Financial Group invested in 21,200 shs. Royal Savings Bank Of Canada stated it has 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP).

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Ratings Coverage

In total 3 analysts cover Oramed Pharmaceuticals (NASDAQ:ORMP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:ORMP)’s analyst reports since November 22, 2017 according to StockzIntelligence Inc. On Wednesday, November 22 H.C. Wainwright maintained the shares of ORMP in report with “Buy” rating. On Monday, December 11 the rating was maintained by B. Riley & Co with “Buy”. Listed here are Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) PTs and latest ratings.

11/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $20 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $20.0
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $25.0 Maintain

ORMP reached $7.13 on during the last trading session after $0.14 change.Currently Oramed Pharmaceuticals Inc. is uptrending after 11.98% change in last April 16, 2017. ORMP has also 15,779 shares volume. ORMP outperformed by 0.43% the S&P 500.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides.The firm is worth $102.98 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.Last it reported negative earnings. The firm operates primarily in Israel.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.